I have managed many domestic special purpose companies in the...

I have managed many domestic special purpose companies in the past. they don't require additional operational staff unless and until the equity holders decide they do (lots of threshold hurdles before that time generally occurs). typically funding is via equity injection or limited recourse loans. we have been led to believe in this case it will be in the form of equity via PYCTx. I don't see any value in speculating - we all want to know and we will when its appropriate. Per WW's input the expectation is human trials might be sooner rather than later - perhaps that means funding required sooner rather than later - perhaps not. This process has been so closely managed so far I have utmost faith. In the spec world having stellar management like we do is a rarity.